BioMarin to Host a Research and Development Day on December 6th

BioMarin to Host a Research and Development Day on December 6th

SAN RAFAEL, Calif., Nov. 27, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) will host a Research and Development Day for the investment
community on Thursday, December 6, 2012 from 8:00 a.m. to 12:00 p.m. at The
Plaza Hotel in New York City. Members of BioMarin's management team and
industry experts will provide an update on the company's product portfolio and
advancements in the research and development pipeline.

Dial-in information
Toll-free number: (877) 303-6313
International number: (631) 813-4734
Conference ID #: 73482446

Replay information
Toll-free number: (855) 859-2056
International number: (404) 537-3406
Conference ID #: 73482446

Interested parties may access a live audio webcast and slides of the
presentation via the investor section of the BioMarin website,
http://www.BMRN.com.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme^® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme^® (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a
50/50 joint venture with Genzyme Corporation; Kuvan^® (sapropterin
dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership
with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and
Firdapse™ (amifampridine), which has been approved by the European Commission
for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product
candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is
currently in Phase III clinical development for the treatment of MPS IVA,
amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in
Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL
(PEGylated recombinant phenylalanine ammonia lyase), which is currently in
Phase II clinical development for the treatment of PKU, BMN-701, a novel
fusion protein of insulin-like growth factor 2 and acid alpha glucosidase
(IGF2-GAA), which is currently in Phase I/II clinical development for the
treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP)
inhibitor, which is currently in Phase I/II clinical development for the
treatment of genetically-defined cancers, and BMN-111, a modified
C-nutriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

BioMarin^®, Naglazyme^®, Kuvan^® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.

The BioMarin Pharmaceutical Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11419

CONTACT: Investors:
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570
        
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo